Recent Updates
Recently added Catalysts
ADPT

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

Key Takeaway: SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Price reaction · baseline $10.73 (2022-07-07 close) · hit after-hours · clean, no other ADPT news in the window
day 0 close · peak
-3.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~174 mo
Minimal dilution risk
Lead asset
Ceftaroline
Phase 3 · Community-acquired Pneumonia, Influenza, COVID-19

Full Press Release Details

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To attend the conference call or webcast, participants should register online. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. The webcast will be archived and available for replay within 24 hours after the event on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Karina Calzadilla, Vice President, Investor Relations
Carrie Mendivil, Gilmartin Group
Last updated: Jul 8, 2022